menu
    • menu
    [{"orgOrder":0,"company":"Experimental Drug Development Centre","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"ETC-159","moa":"Protein-serine O-palmitoleoyltransferase porcupine (PORCN)","graph1":"Oncology","graph2":"Phase I","graph3":"Experimental Drug Development Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Experimental Drug Development Centre \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"Experimental Drug Development Centre \/ PPD"},{"orgOrder":0,"company":"Duke-NUS Medical School","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ETC-159","moa":"||Wnt signalling pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Duke-NUS Medical School","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke-NUS Medical School \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Duke-NUS Medical School \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for ETC-159

    Menu

    ETC-159

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Duke-NUS Medical School

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Duke-NUS Medical School

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETC-159,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Made-in-Singapore Cancer Drug ETC-159 Advances Further In Clinical Trials

                            Details : The first dose of ETC-159 has been administered to patients in this new phase of clinical testing, which for the first time, will look at efficacy in addition to assessing the safety of ETC-159 in treating different types of cancers.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 31, 2020

                            Lead Product(s) : ETC-159,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Experimental Drug Development Centre

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Experimental Drug Development Centre

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETC-159

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembr...

                            Details : ETC-1922159 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 13, 2015

                            Lead Product(s) : ETC-159

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth